| Dr Omar Rashid Qureshi, DO | |
|
33 Electric Ave Ste 102, Fitchburg, MA 01420-7954 | |
| (978) 343-7246 | |
| (978) 343-7247 |
| Full Name | Dr Omar Rashid Qureshi |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 13 Years |
| Location | 33 Electric Ave Ste 102, Fitchburg, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760776892 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | 268137 (Massachusetts) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 268139 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Healthalliance Hospitals, Inc | Leominster, MA | Hospital |
| Heywood Hospital - | Gardner, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Premier Pain Management Pllc | 9638412497 | 2 |
News Archive
Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p<0.005) in improving overall sleep efficiency at night one and at the end of week four in patients with primary insomnia. MK-4305 was generally well-tolerated in the study. Orexins are neuropeptides (chemical messengers) that are released by specialized neurons in the hypothalamus region of the brain and are believed to be an important regulator of the brain's sleep-wake process.
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
A recent study by biological engineers at the Johns Hopkins Applied Physics Laboratory in Laurel, Maryland, demonstrated a significant advancement in the preservation of particular types of medicines, known as protein expression systems, for field applications - enabling those medicines to be stored and reconstituted on site in adverse conditions.
Reuters examines how budget debates in Congress "could undo" President Barack Obama's "'smart power' approach, which elevates diplomacy and development alongside military power as guarantors of U.S. security in a rapidly changing world." Programs run through the State Department and USAID that provide "food aid to hungry countries, improved medical services for expectant mothers and the U.S. response to natural disasters such as earthquakes and droughts could be hit in a major scale-back of U.S. assistance," the news agency writes.
› Verified 7 days ago
| Entity Name | Premier Pain Management Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386102614 PECOS PAC ID: 9638412497 Enrollment ID: O20190517000611 |
News Archive
Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p<0.005) in improving overall sleep efficiency at night one and at the end of week four in patients with primary insomnia. MK-4305 was generally well-tolerated in the study. Orexins are neuropeptides (chemical messengers) that are released by specialized neurons in the hypothalamus region of the brain and are believed to be an important regulator of the brain's sleep-wake process.
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
A recent study by biological engineers at the Johns Hopkins Applied Physics Laboratory in Laurel, Maryland, demonstrated a significant advancement in the preservation of particular types of medicines, known as protein expression systems, for field applications - enabling those medicines to be stored and reconstituted on site in adverse conditions.
Reuters examines how budget debates in Congress "could undo" President Barack Obama's "'smart power' approach, which elevates diplomacy and development alongside military power as guarantors of U.S. security in a rapidly changing world." Programs run through the State Department and USAID that provide "food aid to hungry countries, improved medical services for expectant mothers and the U.S. response to natural disasters such as earthquakes and droughts could be hit in a major scale-back of U.S. assistance," the news agency writes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Omar Rashid Qureshi, DO 33 Electric Ave Ste 102, Fitchburg, MA 01420-7954 Ph: (978) 343-7246 | Dr Omar Rashid Qureshi, DO 33 Electric Ave Ste 102, Fitchburg, MA 01420-7954 Ph: (978) 343-7246 |
News Archive
Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p<0.005) in improving overall sleep efficiency at night one and at the end of week four in patients with primary insomnia. MK-4305 was generally well-tolerated in the study. Orexins are neuropeptides (chemical messengers) that are released by specialized neurons in the hypothalamus region of the brain and are believed to be an important regulator of the brain's sleep-wake process.
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
A recent study by biological engineers at the Johns Hopkins Applied Physics Laboratory in Laurel, Maryland, demonstrated a significant advancement in the preservation of particular types of medicines, known as protein expression systems, for field applications - enabling those medicines to be stored and reconstituted on site in adverse conditions.
Reuters examines how budget debates in Congress "could undo" President Barack Obama's "'smart power' approach, which elevates diplomacy and development alongside military power as guarantors of U.S. security in a rapidly changing world." Programs run through the State Department and USAID that provide "food aid to hungry countries, improved medical services for expectant mothers and the U.S. response to natural disasters such as earthquakes and droughts could be hit in a major scale-back of U.S. assistance," the news agency writes.
› Verified 7 days ago